Biosynexus, Inc. Acquired By QVT Fund LP; Irwin Scher Named CEO Of Biosynexus Incorporated
10/19/2005 5:08:54 PM
GAITHERSBURG, Md. & NEW YORK--(BUSINESS WIRE)--June 14, 2005--Biosynexus Incorporated, a biotechnology-pharmaceutical company that is commercializing a portfolio of products for the prevention and treatment of infectious diseases, announced today that Biosynexus became a wholly owned subsidiary of QVT Fund LP, as of May 26th, 2005. Biosynexus also announced that Dr. Irwin Scher has been appointed Chief Executive Officer.
Prior to joining Biosynexus, Dr. Scher served as a consultant to the CEO of Merck KGaA and as Vice President, Global Clinical Research & Development at Merck KGaA. Prior to this, he held the roles of Senior Vice President, Drug Development and Medical Affairs at Astra-Zeneca, and of Vice President Drug Development at Merck & Company Inc. Dr. Scher is a veteran of academic medicine, having spent fourteen years at the National Naval Medical Center, the Naval Medical Research Institute and the Uniformed Services University as the director of Rheumatology.
comments powered by